Stock COPN COSMO PHARMACEUTICALS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Cosmo Pharmaceuticals N.V.

Equities

COPN

NL0011832936

Market Closed - Swiss Exchange
Other stock markets
 11:30:44 2024-05-03 am EDT 		5-day change 1st Jan Change
72.2 CHF +0.84% Intraday chart for Cosmo Pharmaceuticals N.V. +0.84% +41.85%
Apr. 26 Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024 CI
Apr. 25 Cosmo Pharmaceuticals Names New CEO, Chairman MT

Evolution of the average Target Price on Cosmo Pharmaceuticals N.V.

Price target over the last 5 years

History of analyst recommendation changes

2a71dc8a1894.izAJe5U5yOy7VjSeV4U2L0M2dz-Oy4lIu9YOe216J6s.5UFWFP0Pm4faB2fqAOBHVTdwLkriscEQ86c2QwQ8aOjmQ08N_A6qj_kffQ~8f627168dfa96201d6de25d56ea8155e

Analyst Recommendations on Cosmo Pharmaceuticals N.V.

Berenberg Lifts Price Target on Cosmo Pharmaceuticals, Maintains Buy Recommendation MT
Berenberg EU Opportunities Conference FA
Cosmo Pharmaceuticals Partner Medtronic Says GI Genius Endoscopy Lowers Colorectal Polyps Miss Rate MT
Cosmo Pharmaceuticals' GI Genius Device Cuts Adenoma, Polyp Miss Rate in Colonoscopy MT
Cosmo Pharmaceuticals N.V. Detects Study Shows AI Assistance Using GI Genius? Reduces Missed Polyp Rate by Nearly 50% on Initial Colonoscopy CI
COSMO PHARMACEUTICALS N : Research Partners Lowers Price Target on Cosmo Pharmaceuticals, Maintains Buy Recommendation MT
COSMO PHARMACEUTICALS N : Research Partners Lifts Price Target on Cosmo Pharmaceutical, Maintains Buy Recommendation MT
Berenberg European Conference FA
Berenberg USA Conference FA
Berenberg European Conference FA
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
74.09 EUR
Average target price
94.95 EUR
Spread / Average Target
+28.16%
High Price Target
111 EUR
Spread / Highest target
+49.84%
Low Price Target
81.69 EUR
Spread / Lowest Target
+10.26%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cosmo Pharmaceuticals N.V.

Berenberg Bank
Research Capital

Ratings for Cosmo Pharmaceuticals N.V.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. COPN Stock
  4. Consensus Cosmo Pharmaceuticals N.V.